Yunfei F. Yuan
State Key Laboratory Of Oncology In South China
Guangzhou, China
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 108 publications
HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation-Mediated TXNRD1 Stabilization to Suppress Ferroptosis.
Journal: Cancer research
Published: January 20, 2026
Sintilimab and lenvatinib plus hepatic arterial infusion chemotherapy and embolization as conversion therapy for uHCC: A phase 2 trial.
Journal: Med (New York, N.Y.)
Published: October 14, 2025
COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling.
Journal: Clinical and molecular hepatology
Published: September 26, 2025
USP14-mediated metabolic competition impairs CD8+ T cell immunosurveillance in hepatocellular carcinoma.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: September 18, 2025
Dynamic Arginine Methylation of YBX1 Relay Controls Its Phase Separation and Chemoradiotherapy Resistance in Rectal Cancer.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: February 13, 2025
Regulatory factor X1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by transcriptional regulation of BECN1.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: November 19, 2024
Prognosis predictors of hepatocellular carcinoma after hepatectomy following conversion therapy.
Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: July 19, 2024
KLF4 Suppresses the Progression of Hepatocellular Carcinoma by Reducing Tumor ATP Synthesis through Targeting the Mir-206/RICTOR Axis.
Journal: International journal of molecular sciences
Published: May 24, 2024
Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study.
Journal: International immunopharmacology
Published: May 17, 2024
PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma.
Journal: Clinical and experimental medicine
Published: May 10, 2024
Last Updated: 09/26/2026